OVERVIEW

Emergent Reversal of Anticoagulation Vitamin K Antagonist (VKA) and Direct Oral Anticoagulants (DOACs) is organized by Association for the Advancement of Blood & Biotherapies (AABB) and will be held from Jun 05, 2019 - Mar 31, 2022. This Conference has been approved for a maximum of 1.00 continuing education credits/contact hours.

Intended Audience:
Hospitals, Hospital Blood Banks, Medical Directors, Nurses, Physicians, Resident/Fellow, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers.

Topic: Transfusion Medicine.

Program Description:
Four-Factor Prothrombin Complex Concentrate is used for reversal of vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) in the setting of major hemorrhage or urgent need for surgery. This program will describe the efficacy and safety of Four-Factor Prothrombin Complex Concentrate compared to plasma for VKA reversal prior to urgent surgical or invasive procedures. Practical considerations such as fixed versus weight-based dosing will also be explored. Direct oral anticoagulants (DOACs) are replacing VKA because of better safety profile and no need for routine testing. However, bleeding is still a serious complication of DOACs. The second part will discuss the management of DOACs related bleeds and specific antidotes and non-specific agents.

Learning Objectives:
After participating in this educational activity, participants should be able to:
• Discuss common clinical indications for the use of Four-Factor Prothrombin Complex Concentrate.
• Compare and contrast alternative options for anticoagulant reversal including plasma and drug-specific reversal agents.
• Explore practical considerations for use of Four-Factor Prothrombin Complex Concentrate included fixed versus weight-based dosing.

Additional details will be posted as soon as they are available.